Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 21st October 2020 from 07:00 AM to 07:00 PM (BST).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 25, 2019
Previous Article Next Article

1,4-Anhydro-4-seleno-d-talitol (SeTal): a remarkable selenium-containing therapeutic molecule

Author affiliations


It is well accepted that organoselenium compounds are powerful antioxidants that have potential therapeutic benefits. Unfortunately, the therapeutic value of many of these selenium-containing entities is often hampered by low solubility in aqueous solutions, which prevents them from reaching therapeutically relevant doses in plasma. We approached this problem by constructing selenosugars with infinite water solubilities. Work over many years led to the discovery of 1,4-anhydro-4-seleno-D-tallitol (SeTal), which has been shown to accelerate skin-tissue repair, heal wounds in (db/db and wt) rodent and porcine models, and prevent high-glucose-induced endothelial dysfunction in mouse aorta. This lead compound is currently being developed as a topical medicament for a variety of skin-repair scenarios. This article discusses the chemistry that led to the development of our selenium-containing carbohydrates, and showcases the remarkable therapeutic properties of SeTal.

Graphical abstract: 1,4-Anhydro-4-seleno-d-talitol (SeTal): a remarkable selenium-containing therapeutic molecule

Back to tab navigation

Article information

29 Apr 2019
28 May 2019
First published
04 Jun 2019

New J. Chem., 2019,43, 9759-9765
Article type

1,4-Anhydro-4-seleno-D-talitol (SeTal): a remarkable selenium-containing therapeutic molecule

M. J. Davies and C. H. Schiesser, New J. Chem., 2019, 43, 9759
DOI: 10.1039/C9NJ02185J

Social activity

Search articles by author